PCSK9 inhibitors: current status and emerging frontiers in lipid control

References

• Roth GA, Mensah, G. A., Johnson, C. O, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021. doi: 10.1016/j.jacc.2020.11.010
   PubMed Web of Science ®Google Scholar
• Agnello F, Finocchiaro S, Laudani C, et al. A review of polypills for the prevention of atherosclerotic cardiovascular disease. Am Heart J. 2023;266:74–85. doi: 10.1016/j.ahj.2023.08.012
   PubMed Web of Science ®Google Scholar
• Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur Heart J. 2017;38(32):2459–2472. doi: 10.1093/eurheartj/ehx144
   PubMed Web of Science ®Google Scholar
• Visseren FLJ, Mach, F., Smulders, Y. M., et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–3337. doi: 10.1093/eurheartj/ehab484
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell, L Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
   PubMed Web of Science ®Google Scholar
• Mihaylova B, Emberson, J., Blackwell, L. et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–590.
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188. doi: 10.1093/eurheartj/ehz455
   PubMed Web of Science ®Google Scholar
• Cohen J, Pertsemlidis A, Kotowski IK, et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37(2):161–165. doi: 10.1038/ng1509
   PubMed Web of Science ®Google Scholar
• Abifadel M, Varret M, Rabès J-P, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154–156. doi: 10.1038/ng1161
   PubMed Web of Science ®Google Scholar
• Cohen JC, Boerwinkle E, Mosley TH, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264–1272. doi: 10.1056/NEJMoa054013
   PubMed Web of Science ®Google Scholar
• Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res. 2009;50(Suppl(Suppl)):S172–7. doi: 10.1194/jlr.R800091-JLR200
   PubMedGoogle Scholar
• Seidah NG, Awan Z, Chrétien M, et al. PCSK9: a key modulator of cardiovascular health. Circ Res. 2014;114(6):1022–1036. doi: 10.1161/CIRCRESAHA.114.301621
   PubMed Web of Science ®Google Scholar
• Naureckiene S, Ma L, Sreekumar K, et al. Functional characterization of Narc 1, a novel proteinase related to proteinase K. Arch Biochem Biophys. 2003;420(1):55–67. doi: 10.1016/j.abb.2003.09.011
   PubMed Web of Science ®Google Scholar
• Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012;367(20):1891–1900. doi: 10.1056/NEJMoa1201832
   PubMed Web of Science ®Google Scholar
• McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59(25):2344–2353. doi: 10.1016/j.jacc.2012.03.007
   PubMed Web of Science ®Google Scholar
• Lambert G, Thedrez A, Croyal M, et al. The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies. Clin Sci (Lond). 2017;131(4):261–268. doi: 10.1042/CS20160403
   PubMed Web of Science ®Google Scholar
• Shapiro MD, Fazio S. PCSK9 and atherosclerosis - Lipids and beyond. J Atheroscler Thromb. 2017;24(5):462–472. doi: 10.5551/jat.RV17003
   PubMed Web of Science ®Google Scholar
• Ding Z, Liu S, Wang X, et al. Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta. Antioxid Redox Signal. 2015;22(9):760–771. doi: 10.1089/ars.2014.6054
   PubMed Web of Science ®Google Scholar
• Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci. 2007;32(2):71–77. doi: 10.1016/j.tibs.2006.12.008
   PubMed Web of Science ®Google Scholar
• Rashid S, Tavori H, Brown PE, et al. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms. Circulation. 2014;130(5):431–441. doi: 10.1161/CIRCULATIONAHA.113.006720
   PubMed Web of Science ®Google Scholar
• Raal FJ, Giugliano RP, Sabatine MS, et al. PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role. J Lipid Res. 2016;57(6):1086–1096. doi: 10.1194/jlr.P065334
   PubMed Web of Science ®Google Scholar
• Ferri N, Tibolla G, Pirillo A, et al. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis. 2012;220(2):381–386. doi: 10.1016/j.atherosclerosis.2011.11.026
   PubMed Web of Science ®Google Scholar
• Zhu L, Giunzioni, I., Tavori, H., et al. Loss of macrophage low-density lipoprotein receptor-related protein 1 confers resistance to the antiatherogenic effects of tumor necrosis factor-alpha inhibition. Arterioscler Thromb Vasc Biol. 2016;36(8):1483–1495. doi: 10.1161/ATVBAHA.116.307736
   PubMed Web of Science ®Google Scholar
• Desai NR, Giugliano, R. P., Wasserman, S. M., et al. Association between circulating baseline proprotein convertase subtilisin kexin type 9 levels and efficacy of evolocumab. JAMA Cardiol. 2017;2(5):556–560. doi: 10.1001/jamacardio.2016.5395
   PubMed Web of Science ®Google Scholar
• Grune J, Meyborg H, Bezhaeva T, et al. PCSK9 regulates the chemokine receptor CCR2 on monocytes. Biochem Biophys Res Commun. 2017;485(2):312–318. doi: 10.1016/j.bbrc.2017.02.085
   PubMed Web of Science ®Google Scholar
• Qi Z, Hu, L., Zhang, J., et al. PCSK9 (proprotein convertase subtilisin/kexin 9) enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet CD36. Circulation. 2021;143(1):45–61. doi: 10.1161/CIRCULATIONAHA.120.046290
   PubMed Web of Science ®Google Scholar
• Guo J, Bot, I., de Nooijer, R., et al. Leucocyte cathepsin K affects atherosclerotic lesion composition and bone mineral density in low-density lipoprotein receptor deficient mice. Cardiovasc Res. 2009;81(2):278–285. doi: 10.1093/cvr/cvn311
   PubMed Web of Science ®Google Scholar
• Bergeron N, Phan BAP, Ding Y, et al. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. Circulation. 2015;132(17):1648–1666. doi: 10.1161/CIRCULATIONAHA.115.016080
   PubMed Web of Science ®Google Scholar
• Urban D, Pöss J, Böhm M, et al. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol. 2013;62(16):1401–1408. doi: 10.1016/j.jacc.2013.07.056
   PubMed Web of Science ®Google Scholar
• Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376(1):41–51. doi: 10.1056/NEJMoa1609243
   PubMed Web of Science ®Google Scholar
• Chan JC, Piper, D. E., Cao, Q., et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A. 2009;106(24):9820–9825. doi: 10.1073/pnas.0903849106
   PubMed Web of Science ®Google Scholar
• Wang Y, Huang Y, Hobbs HH, et al. Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR. J Lipid Res. 2012;53(9):1932–1943. doi: 10.1194/jlr.M028563
   PubMed Web of Science ®Google Scholar
• Kwon HJ, Lagace TA, McNutt MC, et al. Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci U S A. 2008;105(6):1820–1825. doi: 10.1073/pnas.0712064105
   PubMed Web of Science ®Google Scholar
• Lambert G, Charlton F, Rye K-A, et al. Molecular basis of PCSK9 function. Atherosclerosis. 2009;203(1):1–7. doi: 10.1016/j.atherosclerosis.2008.06.010
   PubMed Web of Science ®Google Scholar
• Shimada YJ, Cannon CP. PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future. Eur Heart J. 2015;36(36):2415–2424. doi: 10.1093/eurheartj/ehv174
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone, N. J., Bailey, A. L., et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019;139(25):e1082–e1143.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097–2107. doi: 10.1056/NEJMoa1801174
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722. doi: 10.1056/NEJMoa1615664
   PubMed Web of Science ®Google Scholar
• Gibbs JP, Doshi S, Kuchimanchi M, et al. Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). J Clin Pharmacol. 2017;57(5):616–626. doi: 10.1002/jcph.840
   PubMed Web of Science ®Google Scholar
• Dadu RT, Ballantyne CM. Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol. 2014;11(10):563–575. doi: 10.1038/nrcardio.2014.84
   PubMed Web of Science ®Google Scholar
• Sabatine MS. PCSK9 inhibitors: clinical evidence and implementation. Nat Rev Cardiol. 2019;16(3):155–165. doi: 10.1038/s41569-018-0107-8
   PubMed Web of Science ®Google Scholar
• Ridker PM, Tardif J-C, Amarenco P, et al. Lipid-reduction variability and antidrug-antibody formation with Bococizumab. N Engl J Med. 2017;376(16):1517–1526. doi: 10.1056/NEJMoa1614062
   PubMed Web of Science ®Google Scholar
• Ridker PM, Revkin J, Amarenco P, et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med. 2017;376(16):1527–1539. doi: 10.1056/NEJMoa1701488
   PubMed Web of Science ®Google Scholar
• Schroeder KM, Beyer TP, Hansen RJ, et al. Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody. J Lipid Res. 2015;56(11):2124–2132. doi: 10.1194/jlr.M061903
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, Nissen, S. E., Rader, D. J., et al. Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled phase 2 study. Eur Heart J. 2016;37(17):1360–1369. doi: 10.1093/eurheartj/ehv707
   PubMed Web of Science ®Google Scholar
• Baruch A, Mosesova S, Davis JD, et al. Effects of RG7652, a monoclonal antibody against PCSK9, on LDL-C, LDL-C subfractions, and inflammatory biomarkers in patients at high risk of or with established coronary Heart disease (from the phase 2 EQUATOR study). Am J Cardiol. 2017;119(10):1576–1583. doi: 10.1016/j.amjcard.2017.02.020
   PubMed Web of Science ®Google Scholar
• Levisetti M, Joh T, Wan H, et al. A phase I randomized study of a specifically engineered, pH-Sensitive PCSK9 inhibitor RN317 (PF-05335810) in hypercholesterolemic Subjects on statin therapy. Clin Transl Sci. 2017;10(1):3–11. doi: 10.1111/cts.12430
   PubMed Web of Science ®Google Scholar
• Zhang L, McCabe T, Condra JH, et al. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes. Int J Biol Sci. 2012;8(3):310–327. doi: 10.7150/ijbs.3524
   PubMed Web of Science ®Google Scholar
• Xu M, Lei G, Chen M, et al. Development of a novel, fully human, anti-PCSK9 antibody with potent hypolipidemic activity by utilizing phage display-based strategy. EBioMedicine. 2021;65:103250. doi: 10.1016/j.ebiom.2021.103250
   PubMed Web of Science ®Google Scholar
• Toth S, Pella D, Fedacko J. Vaccines targeting PSCK9 for the treatment of hyperlipidemia. Cardiol Ther. 2020;9(2):323–332. doi: 10.1007/s40119-020-00191-6
   PubMed Web of Science ®Google Scholar
• Mitchell T, Chao G, Sitkoff D, et al. Pharmacologic profile of the adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering. J Pharmacol Exp Ther. 2014;350(2):412–424. doi: 10.1124/jpet.114.214221
   PubMed Web of Science ®Google Scholar
• Galabova G, Brunner S, Winsauer G, et al. Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management. PLoS One. 2014;9(12):e114469. doi: 10.1371/journal.pone.0114469
   PubMed Web of Science ®Google Scholar
• Johns DG, Campeau, L. C., Banka, P., et al. Orally bioavailable macrocyclic peptide that inhibits binding of PCSK9 to the low density lipoprotein receptor. Circulation. 2023;148(2):144–158. doi: 10.1161/CIRCULATIONAHA.122.063372
   PubMed Web of Science ®Google Scholar
• Josephson K, Ricardo A, Szostak JW. mRNA display: from basic principles to macrocycle drug discovery. Drug Discov Today. 2014;19(4):388–399. doi: 10.1016/j.drudis.2013.10.011
   PubMed Web of Science ®Google Scholar
• Dixon DL, Trankle C, Buckley L, et al. A review of PCSK9 inhibition and its effects beyond LDL receptors. J Clin Lipidol. 2016;10(5):1073–1080. doi: 10.1016/j.jacl.2016.07.004
   PubMed Web of Science ®Google Scholar
• Lintner NG, McClure KF, Petersen D, et al. Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain. PLoS Biol. 2017;15(3):e2001882. doi: 10.1371/journal.pbio.2001882
   PubMed Web of Science ®Google Scholar
• Cong L, Ran FA, Cox D, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339(6121):819–823. doi: 10.1126/science.1231143
   PubMed Web of Science ®Google Scholar
• Ding Q, Strong A, Patel KM, et al. Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res. 2014;115(5):488–492. doi: 10.1161/CIRCRESAHA.115.304351
   PubMed Web of Science ®Google Scholar
• Kobiyama K, Saigusa R, Ley K. Vaccination against atherosclerosis. Curr Opin Immunol. 2019;59:15–24. doi: 10.1016/j.coi.2019.02.008
   PubMed Web of Science ®Google Scholar
• Coppinger C, Movahed MR, Azemawah V, et al. A comprehensive review of PCSK9 inhibitors. J Cardiovasc Pharmacol Ther. 2022;27:10742484221100107. doi: 10.1177/10742484221100107
   Web of Science ®Google Scholar
• Sahebkar A, Momtazi-Borojeni AA, Banach M. PCSK9 vaccine: so near, yet so far! Eur Heart J. 2021;42(39):4007–4010. doi: 10.1093/eurheartj/ehab299
   PubMed Web of Science ®Google Scholar
• Landlinger C, Pouwer MG, Juno C, et al. The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice. Eur Heart J. 2017;38(32):2499–2507. doi: 10.1093/eurheartj/ehx260
   PubMed Web of Science ®Google Scholar
• Momtazi-Borojeni AA, Jaafari MR, Badiee A, et al. Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system. Atherosclerosis. 2019;283:69–78. doi: 10.1016/j.atherosclerosis.2019.02.001
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016;316(22):2373–2384. doi: 10.1001/jama.2016.16951
   PubMed Web of Science ®Google Scholar
• Koren MJ, Sabatine, M. S., Giugliano, R. P., et al. Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 years from the Open-label OSLER-1 extension study. JAMA Cardiol. 2017;2(6):598–607. doi: 10.1001/jamacardio.2017.0747
   PubMed Web of Science ®Google Scholar
• Debette S, Beiser, A., DeCarli, C., et al. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the framingham offspring study. Stroke. 2010;41(4):600–606. doi: 10.1161/STROKEAHA.109.570044
   PubMed Web of Science ®Google Scholar
• Santos RD, Ruzza A, Hovingh GK, et al. Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020;383(14):1317–1327. doi: 10.1056/NEJMoa2019910
   PubMed Web of Science ®Google Scholar
• Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311(18):1870–1882. doi: 10.1001/jama.2014.4030
   PubMed Web of Science ®Google Scholar
• Koren MJ, Lundqvist P, Bolognese M, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2531–2540. doi: 10.1016/j.jacc.2014.03.018
   PubMed Web of Science ®Google Scholar
• Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2541–2548. doi: 10.1016/j.jacc.2014.03.019
   PubMed Web of Science ®Google Scholar
• Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):331–340. doi: 10.1016/S0140-6736(14)61399-4
   PubMed Web of Science ®Google Scholar
• Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370(19):1809–1819. doi: 10.1056/NEJMoa1316222
   PubMed Web of Science ®Google Scholar
• White HD, Schwartz GG, Szarek M, et al. Alirocumab after acute coronary syndrome in patients with a history of heart failure. Eur Heart J. 2022;43(16):1554–1565. doi: 10.1093/eurheartj/ehab804
   PubMed Web of Science ®Google Scholar
• Blom DJ, Harada-Shiba M, Rubba P, et al. Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: the ODYSSEY HoFH trial. J Am Coll Cardiol. 2020;76(2):131–142. doi: 10.1016/j.jacc.2020.05.027
   PubMed Web of Science ®Google Scholar
• Räber L, Ueki, Y., Otsuka, T., et al. Effect of Alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA. 2022;327(18):1771–1781. doi: 10.1001/jama.2022.5218
   PubMed Web of Science ®Google Scholar
• Koskinas KC, Windecker S, Pedrazzini G, et al. Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS). J Am Coll Cardiol. 2019;74(20):2452–2462. doi: 10.1016/j.jacc.2019.08.010
   PubMed Web of Science ®Google Scholar
• Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366(12):1108–1118. doi: 10.1056/NEJMoa1105803
   PubMed Web of Science ®Google Scholar
• Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489–1499. doi: 10.1056/NEJMoa1501031
   PubMed Web of Science ®Google Scholar
• Cannon CP, Cariou B, Blom D, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015;36(19):1186–1194. doi: 10.1093/eurheartj/ehv028
   PubMed Web of Science ®Google Scholar
• Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet. 383(9911): 60–68. doi:10.1016/S0140-6736(13)61914-5
   PubMed Web of Science ®Google Scholar
• Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520–1530. doi: 10.1056/NEJMoa1913805
   PubMed Web of Science ®Google Scholar
• Mehta SR, Pare G, Lonn EM, et al. Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial. EuroIntervention. 2022;18(11):e888–e896. doi: 10.4244/EIJ-D-22-00735
   PubMed Web of Science ®Google Scholar
• Ray KK, Kallend D, Leiter LA, et al. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J. 2022;43(48):5047–5057. doi: 10.1093/eurheartj/ehac615
   PubMed Web of Science ®Google Scholar
• Koren MJ, Hofherr, A., Schumi, J. et al. ETESIAN: a phase 2b study of the efficacy, safety and tolerability of AZD8233, a PCSK9-targeted antisense oligonucleotide in patients with dyslipidemia. J Am Coll Cardiol. 2022;79(9_Supplement):1475–1475. doi: 10.1016/S0735-1097(22)02466-4
   Web of Science ®Google Scholar
• Roth EM, Goldberg AC, Catapano AL, et al. Antidrug antibodies in patients treated with Alirocumab. N Engl J Med. 2017;376(16):1589–1590. doi: 10.1056/NEJMc1616623
   PubMed Web of Science ®Google Scholar
• Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507–1519. doi: 10.1056/NEJMoa1912387
   PubMed Web of Science ®Google Scholar
• Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430–1440. doi: 10.1056/NEJMoa1615758
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European atherosclerosis Society (EAS). Eur Heart J. 2019;41(1):111–188. doi: 10.1093/eurheartj/ehz455
   Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–2397. doi: 10.1056/NEJMoa1410489
   PubMed Web of Science ®Google Scholar
• Desai NR, Kohli P, Giugliano RP, et al. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C assessment with proprotein convertase subtilisin kexin type 9 monoclonal antibody inhibition combined with statin therapy (LAPLACE)-thrombolysis in myocardial infarction (TIMI) 57 trial. Circulation. 2013;128(9):962–969. doi: 10.1161/CIRCULATIONAHA.113.001969
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Banka P, Mendez G, et al. Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616. J Am Coll Cardiol. 2023;81(16):1553–1564. doi: 10.1016/j.jacc.2023.02.018
   PubMed Web of Science ®Google Scholar
• Grzesk G, Dorota B, Wołowiec Ł, et al. Safety of PCSK9 inhibitors. Biomed Pharmacother. 2022;156:113957. doi: 10.1016/j.biopha.2022.113957
   PubMed Web of Science ®Google Scholar
• Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: developed by the task force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2021;42(34):3227–3337. doi: 10.1093/eurheartj/ehab484
   PubMed Web of Science ®Google Scholar
• Lambert G, Sjouke B, Choque B, et al. The PCSK9 decade. J Lipid Res. 2012;53(12):2515–2524. doi: 10.1194/jlr.R026658
   PubMed Web of Science ®Google Scholar
• Cicero AF, Tartagni E, Ertek S. Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data. Expert Opin Drug Saf. 2014;13(8):1023–1030. doi: 10.1517/14740338.2014.932348
   PubMed Web of Science ®Google Scholar
• Robinson JG, Farnier M, Krempf M, et al. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. N Engl J Med. 2015;372(16):1489–1499. doi: 10.1056/NEJMoa1501031
   PubMed Web of Science ®Google Scholar
• Ballantyne Christie M, Banka P, Mendez G, et al. Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616. J Am Coll Cardiol. 2023;81(16):1553–1564. doi: 10.1016/j.jacc.2023.02.018
   PubMed Web of Science ®Google Scholar